Related Stories
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
Key Excerpts from Article on Website of Reuters
Posted: December 11th, 2023
https://www.reuters.com/investigates/special-report/health-o...
Drugmaker Novo Nordisk paid U.S. medical professionals at least $25.8 million over a decade in fees and expenses related to its weight-loss drugs [Wegovy and Saxenda], a Reuters analysis found. It concentrated that money on an elite group of obesity specialists who advocate giving its powerful and expensive drugs to tens of millions of Americans. Those payments are part of a campaign to convince U.S. doctors to make Wegovy one of the most widely prescribed drugs in history – and to persuade skeptical insurers to pay for it. Overall, at least 57 U.S. physicians each accepted at least $100,000 from Novo in payments associated with Wegovy or Saxenda. They were an influential group: Forty-one were obesity specialists who run weight-management clinics, work at academic hospitals, write obesity-treatment guidelines or hold top positions at medical societies, according to a Reuters review. "As sales grow, Medicare and the insurance industry come under intense pressure to pay for these hugely expensive drugs,” [Former dean of the US military's medical school Dr. Arthur] Kellermann said. “The end result is that everybody's healthcare costs go up.” U.S. and European regulators are studying whether GLP-1 drugs can cause suicidal thoughts. Reuters reported in September that at least 265 reports have been filed with the FDA since 2010 describing suicidal ideation or behavior in patients taking these drugs. Thirty-six reports described a death by suicide or suspected suicide.
Note: The money behind these obesity drug makers is staggering. The economic value of Novo Nordisk soared to over $420 billion, which exceeds the entire GDP of Denmark, its home country. As Lee Fang reports in this investigative piece on the issue, “The company is growing so fast, bringing in so many American dollars, that the Danish central bank recently devalued its currency to keep it in line with the euro.” For more along these lines, read the growing reports of concerning adverse side effects from these weight-loss drugs.
Related Stories
Latest News
Key News Articles from Years Past
